Skip to main content

Coronavirus Disease 2019 (COVID-19)

Frank J. Domino, MD, Robert Baldor, Kathleen Barry, MD, Jeremy Golding, MD and Mark B. Stephens, MD Reviewed 11/2020
Email

Send Email

Recipient(s) will receive an email with a link to 'Coronavirus Disease 2019 (COVID-19)' and will have access to the topic for 7 days.

Subject: Coronavirus Disease 2019 (COVID-19)

(Optional message may have a maximum of 1000 characters.)

×
 


BASICS

DESCRIPTION

  • Coronavirus Disease 2019 (COVID-19) is a severe acute multi-system respiratory syndrome which was first detected in Wuhan City, Hubei Province, China.

  • The disease results from a novel virus, named coronavirus 2 (SARS-CoV-2).

  • The syndrome leads to multisystem complications including respiratory failure and death, particularly in elderly and immune-compromised individuals.

  • Anthony Fauci, MD gave an outstanding Medicine Grand Rounds at Harvard Medical School on September 10, 2020, covering all aspects of this virus and illness. It can be viewed at https://player.vimeo.com/video/456649458.

EPIDEMIOLOGY

Incidence

ALERT

A multisystem inflammatory syndrome (MIS-C) related to COVID-19, similar to Kawasaki disease (toxic shock syndrome), is reported in children. It is a "post-infectious immune response," associated with a positive test either for SARS-CoV-2 or for antibodies to the virus (2) (https://emergency.cdc.gov/han/2020/han00432.asp).

  • Common findings in MIS-C include the need for respiratory support, cardiovascular and clotting problems as well as gastrointestinal symptoms and skin rashes. Children with MIS-C often require intensive care (3).

 
  • Racial disparities are evident in the U.S., with African Americans being disproportionately impacted. Age-adjusted hospitalizations are highest among non-Hispanic, American Indian, Alaska Native and Black persons, followed by Hispanic or Latino individuals (4).

  • Prevalence: An ongoing seroprevalence study from the Centers for Disease Control (CDC) shows estimates from ten sites around the United States ranging from 1–7% (5).

  • Children represent ~10% of COVID cases (6).

ETIOLOGY AND PATHOPHYSIOLOGY

  • A novel (new) coronavirus (SARS-CoV-2) causes the coronavirus disease COVID-19.

  • SARS-CoV-2 is related to bat coronaviruses and to other Severe Acute Respiratory Syndrome (SARS) coronaviruses.

  • It is believed to evolve in animals including camels, cats, and bats.

  • Virology: SARS-CoV-2 is a positive-sense single stranded RNA virus (+ssRNA), a beta-coronavirus belonging to the same subgenus as the virus responsible for the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). The SARS-CoV-2 virus uses the angiotensin-converting enzyme 2 (ACE-2) receptor for cellular entry.

    • A less virulent form of the virus may explain why some patients get severely ill while others do not. A retrospective analysis in Singapore compared outcomes of those infected with the SARS-CoV-2 variant with a 382-nucleotide deletion (Δ382) only vs. infected with wild-type only vs. those infected with both types.  Hypoxia requiring supplemental oxygen occurred in no patients infected with Δ382 virus alone but in ~30% of those in the other two groups. After multivariable adjustment, Δ382 virus was associated with a ~90% reduction in the odds of hypoxia requiring oxygen. Patients with the 382-nucleotide deletion variant had lower levels of inflammatory markers (7).

  • Initial spreading for this novel coronavirus appears to have come from a bat reservoir (8).

  • For over 95% of infected persons, symptoms appear within 11.5 days. Median incubation time to is about was 5.5 days (9).

  • Based upon data from the cruise ship Diamond Princess of 96 asymptomatic, infected people, just 11 developed COVID-19 symptoms at a median of 4 days after first PCR result. For patients who never developed symptoms, median time between first positive PCR and the first negative result was 9 days. By day 15 after the first positive result, 90% of the patients had resolved infection (defined as two negative PCR results), but the resolution took longer among older patients (10).

  • Retrospective cohort study found the median duration of viral shedding to be up to 20 days, with some cases as long as 37 days.

  • The estimated median incubation time is 7–76 days (90th percentile is 14–28 days; 10% of patients will have an incubation period longer than 14 days (11).

  • Symptoms develop because of viral effects on pulmonary tissue, and the associated immune response ("cytokine storm").

  • The virus affects the pulmonary and systemic vasculature, resulting in venous and arterial thrombosis including stroke, pulmonary embolism, and myocardial infarction, even in younger patients not normally considered to be at high risk for these problems.

  • A retrospective analysis of patients in New York City emergency departments who underwent computed tomography pulmonary angiography (CTPA) between April 1 and May 1, 2020 found 18.8% of CTPA studies were positive for PE compared to 7.6% during the same time period in 2019 (12).

  • Severe COVID-19 is associated with "hyperferritinemic syndrome" which includes: macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD), catastrophic antiphospholipid syndrome (CAPS) and septic shock. This systemic reaction is characterized by high serum ferritin and a life-threatening hyper-inflammation sustained by a cytokines storm which eventually leads to multi-organ failure (13).

  • Presymptomatic COVID-19 infection is defined as being infected but not yet expressing symptoms. Asymptomatic COVID-19 infection is relatively rare, as most patients who are infected do develop some symptoms, but these symptoms are often minor and discounted by the patient.

  • A systematic review of 50,155 patients from 41 studies with confirmed COVID-19 found the rate of asymptomatic infection was 15.6% (95% CI: 10.1%-23.0%). Ten of the included studies identified rate of presymptomatic patients (were asymptomatic at screening and developed symptoms during follow-up) to be 48.9% (95% CI: 31.6%-66.2%). The pediatric rate of asymptomatic infection was found to be 27.7% (95% CI: 16.4%-42.7%), which is much higher than adult patients (14).

  • Coagulopathy associated with COVID-19 infection includes includes illness ranging from mild thrombocytopenia and rare prolongations of prothrombin time (PT) or partial thromboplastin time (PTT) resulting in increased risk for thrombosis and bleeding. Venous thromboembolism (VTE) was radiologically confirmed in, on average, 4.8% of patients, ranging from 7.6% in those critically ill and 3.1% in non–critically ill patients. The rate of arterial thromboembolism was 2.8% overall, with 5.6% in critically ill patients and 1.2% in non–critically ill patients. Bleeding was found in 4.8% of patients, ranging from 7.6% in critically ill patients to 3.1% in non–critically ill patients; the rate of major bleeding was 2.3% overall, but as high as 5.6% in critically ill patients.

    • Researchers compared the neutrophil activation state from severe COVID-19 cases to patients with less severe disease (requiring only supplemental oxygen) and found those with severe infections had neutrophil activation marker CD177 highly upregulated, had highly activated platelets, and had dysregulated thrombosis cascades compared with less severe infections (15).

  • Thrombosis was predicted by increased by D-dimer level at admission (>2500 ng/mL; odds ratio, 6.79), elevated platelet count, C-reactive protein, and erythrocyte sedimentation rate.

  • Bleeding was predicted by elevated D-dimer level at admission (>2500 ng/mL; OR, 3.56) and by excess thrombocytopenia (16).

RISK FACTORS

  • Travel from countries of the world or specific regions that are experiencing outbreaks

  • The U.S. State Department issues travel bans and/or advisories as conditions change around the world, and advice can be found at https://travel.state.gov.

  • Spread primarily via respiratory droplets produced when an infected person coughs or sneezes

  • Risk factors for severe COVID infection include age over 65 or older, chronic kidney chronic obstructive pulmonary disease, obesity (BMI ≥ 30, risk of death: (OR = 1.71; 95% CI, 0.8-3.64) for BMI ≥ 35, risk of death: OR of 12.1 (95% CI, 3.25-45.1) (17), serious heart conditions (e.g. heart failure, coronary artery disease, cardiomyopathies), sickle cell disease, type 2 diabetes, and being immunocompromised after a solid organ transplant. The more of these conditions people have, the higher their risk. For pediatric patients, the CDC states: "Children who are medically complex, who have neurologic, genetic, metabolic conditions, or who have congenital heart disease are at higher risk for severe illness from COVID-19 than other children" (18).

  • Clinical risk factors for severe disease include chest radiography abnormality, age, hemoptysis, dyspnea, unconsciousness, number of comorbidities, cancer history, neutrophil-to-lymphocyte ratio, lactate dehydrogenase, and direct bilirubin; these can be evaluated using a web-based risk calculator (19).

  • Proton pump inhibitor (PPI) use was found to increase COVID-19 risk; an online survey in the U.S. of 53,130 adults found 6.4% reporting a positive COVID-19 test was 2.15 for once-daily PPIs and an odds ratio of 3.67 for twice-daily use. No such relationship was found with histamine-2 receptor antagonist use (20).

  • Vitamin D deficiency:

    • A retrospective cohort study of 489 COVID-19 patients found after multivariate analysis that testing positive for COVID-19 was associated with age up to 50 years (RR=1.06; 95% CI 101–1.09; not being white (RR=2.54; 95% CI 1.26–5.12); and having vitamin D deficiency (RR=1.77; 95% CI 1.12–2.81) compared to sufficient vitamin D levels (21).

    • A pilot trial of early 25-hydroxyvitamin D treatment in hospitalized COVID-19 patients reduced ICU admissions (2% in the treated group vs. 50% in placebo group) and concerning discharge, 0% of the vitamin D group died and all were discharged to home, while in the placebo group, ~8% died, with the rest discharged to home (22).

    • Observational study of 235 Iranian COVID patients admitted to the hospital found in those over 40, 20% had insufficient vitamin D levels (<30 ng/mL) on admission and ~90% who died had insufficient levels. The authors noted having a sufficient serum vitamin D level, lower levels of C-reactive protein, and higher total blood lymphocyte count, theorizing higher vitamin D levels resulted in improved the immune function (23). 

  • Blood group A: study comparing the genomes of ~1600 people with severe COVID-19 in Italy and Spain with controls found blood group A was associated with a 45% increased risk for COVID-19 respiratory failure, while blood group O was associated with a 35% lower risk (24).

  • Factors independently associated with an increased risk of in-hospital death were:

    • Age greater than 65 years (mortality of 10.0%, vs. 4.9% among those <65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41)

    • Coronary artery disease (10.2%, vs. 5.2% among those without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51)

    • Heart failure (15.3%, vs. 5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79)

    • Cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, 1.95; 95% CI, 1.33 to 2.86)

    • Chronic obstructive pulmonary disease (14.2%, vs. 5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40)

    • Current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds ratio, 1.79; 95% CI, 1.29 to 22.47)

ALERT

Pregnancy increases risk of ICU admission (1.5%) vs. non-pregnant (0.9%), and risk for mechanical ventilation 0.5% vs. 0.3%. Mortality rates are not different (25).

 
  • Pregnancy and breastfeeding do not increase vertical transmission. Researchers compared data on ~80 neonates whose mothers were SARS-CoV-2 positive. About 80% of these children roomed with their mother. Mothers wore surgical masks when near their infant and used good hand and breast hygiene. At 14 days, none of the neonates tested positive (26). A systematic review of pregnancy-related SARS-CoV-2 infection found the risk of maternal intensive care unit admission was 3.0% (critical disease diagnosis [defined as respiratory failure, septic shock, and multiorgan dysfunction or failure] was 1.4%), with no deaths reported. Rate of preterm birth was 20.1% (~10%-11% in non-infected births worldwide); the cesarean section rate was 84.7% (almost triple the baseline rate in the three included countries). Vertical transmission did not occur; rates of neonatal death was found to be 0.3% (27).

  • A study of SARS-CoV-2 positive women who submitted breast milk samples evaluated by reverse transcriptase–polymerase chain reaction found no viral particles, implying breastfeeding when infected with the virus is not likely to transmit infection (28).

  • In the U.S., 40% adults report at least one adverse mental or behavioral health problem: 31% reported symptoms of anxiety or depression, 26% had symptoms of trauma- and stressor-related disorder linked to the pandemic, 13% began or increased substance use; ~11% said they had seriously considered suicide in the prior 30 days. Those at greatest risk of mental health issues include: young adults, Hispanic and African Americans, essential workers, unpaid caregivers for adults, and those with preexisting psychiatric conditions (29).

GENERAL PREVENTION

  • Population health:

    • Containment efforts (quarantine, universal testing, rapid identification of illness, contact tracing) are effective. When disease increases faster than containment can control (as in the U.S., Spain, Italy), mitigation strategies are initiated (hand hygiene, travel restrictions, school closures, and social distancing).

    • Physical distancing of at least 1 meter (preferably 2 meters) reduces viral transmission; use of face masks reduces the risk of infection as does proper use of eye protection (30).

  • Social distancing:

    • Keeping six feet apart from others, closing of schools, workplaces, meetings, social and religious gatherings, and sporting events

    • Minimizing contact with others and closure of nonessential business is effective at stopping the exponential spread of the virus (31).

    • "Close contact" was redefined as being within 6 feet of an infected person for at least 15 minutes over a 24-hour period beginning 2 days before symptom onset (or 2 days before testing in asymptomatic patients). Previously, the 15-minute exposure window was continuous (32).

    • Cell phone tracking in the U.S. found decreases in mobility were strongly associated with decreases in COVID-19 case growth. Until a COVID-19 vaccine is widely available, physical distancing is one of the primary measures to combat disease spread (33).

    • Transmission of viruses was lower with physical distancing of 1 m or more, compared with a distance of less than 1 m (n=10 736, pooled adjusted odds ratio [aOR] 0·18, 95% CI 0·09 to 0·38; risk difference [RD] –11·5 to –7·5; moderate certainty).

    • Protection increases as distance is lengthened (change in relative risk [RR] 2·02 per m; pinteraction=0·041; moderate certainty).

    • Social distancing resulted in decreased rate of childhood infection disease (acute otitis media, bronchiolitis, common cold, croup, gastroenteritis, influenza, nonstreptococcal pharyngitis, pneumonia, sinusitis, skin and soft tissue infections, streptococcal pharyngitis, and urinary tract infection (UTI) based upon observational cohort study from a large pediatric primary care network in Massachusetts. Rates of influenza, croup, and bronchiolitis went to <1 case per 100,000 (34).

  • Face masks

    • Wearing masks in public reduces risk of transmission to others (35,36).

    • N95 confer the greatest protection (30).

    • The CDC updated their recommendations on masks, stating they prevent an infected person from spreading the infection AND effectively filter to prevent the mask wearer from contracting an infection (37).

    • Convert a medical mask to higher efficiency with 3 rubber bands to approximate the protection from an N95 mask: https://www.fixthemask.com/make-it#3-rubber-bands.

    • Health care workers who added a face shield to a face mask reduced their personal infection rate almost 100% in an observational study from India (38).

    • Universal use of face masks decreases the effective reproduction number. Re below 1 (meaning each infected person will infect less than one person) mitigates spread (39). Face masks are beneficial in preventing an ill individual from spreading the infection and in preventing well individuals from inhaling infectious particles and becoming ill. "My mask protects you; your mask protects me."

    • Face mask reduces risk of infection (n=2647; aOR 0·15, 95% CI 0·07 to 0·34, RD –14·3%, –15·9 to –10·7; low certainty), with stronger associations with N95 or similar respirators compared with disposable surgical masks or similar (e.g. reusable 12–16-layer cotton masks; pinteraction=0·090; posterior probability >95%, low certainty) (30).

    • Face masks, physical distancing, social isolation, and contact tracing are current efforts to contain the COVID-19 pandemic (40).

    • Face masks do not increase CO2 retention. A study of 15 physicians without lung disease and 15 veterans with severe chronic obstructive pulmonary disease (COPD) found no significant changes in end-tidal CO2 or oxygen saturation at 5 and 30 minutes of mask wearing; during a 6-minute walk test, patients with COPD did not demonstrate CO2 retention while wearing a mask (41).

    • High-speed camera evaluation of respiratory droplets expelled during speaking, coughing, and sneezing suggests that a 3-layer surgical mask was the most effective at limiting droplet spread. A 2-layer cloth cotton mask was more effective during coughing and sneezing than one made from a single layer, but even a single-layer mask was better than no mask (42).

    • Theoretical data finds N95 masks most efficacious, followed by surgical masks, polypropylene masks and handmade cotton face coverings. Gaiter-type fleece coverings converted larger respiratory droplets into numerous smaller droplets which can travel further and were considered “counterproductive” (43). 

    • Increasing data shows aerosol transmission (with particles able to travel and infect in areas with recirculated air) is likely to occur (44).

    • In the U.S., only about 50% of people were observed wearing masks in public in November 2020 compared to high mask usage countries (South Korea, New Zealand) with very low rates of COVID-19 infections, and subsequent economic recovery. A modeling study estimates that near universal mask use (~95% mask use in public) could save 130,000 lives between September 22, 2020 and February 28, 2021 (45).

  • Hand washing, avoid others if ill, avoid touching face

    • Hand washing for 20 seconds with soap lowers viral carriage and lowers risk of transmission.

  • Humidity: A summary of 10 international studies investigated the influence of humidity on viral (corona viruses SARS-CoV-1, MERS and SARS-CoV-2) spread and survival found air humidity >40% lowers the potential for the virus to be spread through aerosol transmission (46).

  • Social isolation and quarantine:

    • Self-quarantine recommended for all with symptoms of fever or new cough until symptoms resolve

    • Quarantine is recommended if exposed to confirmed COVID-19 infections to reduce infections and deaths.

    • Quarantine of returning international travelers from high risk countries to prevent transmission and death has small benefit.

    • Combination of quarantine and prevention methods (sheltering, school and business closures, social distancing) had a greater effect on disease transmission, use of critical care and deaths compared to quarantine alone.

  • Use of gloves is not recommended for the general population as it may decrease patient hand hygiene and increase carelessness.

  • Exposure to a contaminated surface "is not thought to be the main way the virus spreads" (47).

  • Exposure risk:

    • Children age 10-19 years have been found to spread SARS-CoV-2 to household members more readily than adults. Data from South Korea of ~60,000 contacts of 5700 COVID-19 index patients. Overall, 12% of household contacts were infected, versus 2% of non-household contacts. When the index patient was aged 10–19 years, 19% of household contacts were infected; when the index patient was 30–49, 12% of household members were infected; and when the index patient was 0–9 years, 5% of household contacts were infected (48).

    • Household exposure to SARS-CoV-2 appears to be the most common risk factor for transmission based upon contact tracing, cell phone data and public transportation use. Ten percent of household contacts to index cases became infected vs. 1% from healthcare settings and 0.1% from public transportation. Risk for transmission increased as severity of index case symptoms increased (49).

    • Data from China of 3,410 close contacts of index cases resulted in 3.7% developing infection. Risks for developing infection found 10.3% were household contacts, 0.1% from public transportation, 1.0% healthcare workers, and 1.3% work exposure. It also found the greater the severity of the index-case, the greater the risk of transmission (0.3% in contacts of asymptomatic cases vs. 6.2% in contacts of severe/critical cases) (50).

ALERT
  • School closures: National data on the rates of COVID-19 incidence and mortality across the USA after primary and secondary schools were closed in March 2020 found school closures were associated with a 62% decline in the incidence of COVID-19 per week (vs. a 265% per week before closures). The absolute reduction in COVID-19 incidence associated with school closures was estimated at 424 cases per 100,000 people during days 17–42 after closures. Regarding COVID-19-related mortality, school closures were associated with a decline of 58% per week after school closures. The absolute reduction was estimated at 13 deaths per 100,000 during days 27–42 after closures (51).

  • American Academy of Pediatrics (AAP) released guidelines regarding children and COVID-19 which include cloth face masks being recommended for nearly all children aged ≥ 2 years and guidance on when to test children: having COVID-19 symptoms, having a close contact with a confirmed case, and prior to elective procedures (52).

 
  • Vaccine data:

    • Multiple trials are underway (53).

    • Reports indicate a vaccine has been made available in Russia (no phase 3 trial data available).

    • Strategies include nucleic-acid based vaccines and traditional recombinant technologies (54).

    • Moderna, Inc. reports approaching adequate enrollment of their vaccine. Their Phase 3 study included >7,000 Americans over the age of 65 and >5,000 Americans under 65 with high-risk chronic diseases (diabetes, severe obesity and cardiac disease).

    • The Pfizer and BioNTech SARS-CoV-2 vaccine has demonstrated an efficacy >90% at 7 days after teh second dose is given, based upon a phase 3 trial of ~44,000 volunteers (55).

DIAGNOSIS

Office-based triage 
  • Screen all patients prior to facility entry (https://www.ama-assn.org/practice-management/sustainability/use-covid-19-screening-script-when-reopening-your-practice).

  • Establish Telemedicine protocol.

    • Telemedicine billing guidelines are available (https://www.ama-assn.org/practice-management/digital/ama-telehealth-quick-guide).

  • For those who come to the office:

    • Instruct patients to wear a surgical mask.

    • Maintain strict physical distancing.

    • Remind parents who wish to have a child seen not to bring other family members into the office, and only bring in one child.

  • In general, patients with COVID-19 can be grouped into the following illness categories:

    • Asymptomatic or presymptomatic infection: individuals who test positive for SARS-CoV-2 but have no symptoms

    • Mild illness: individuals who have any of various signs and symptoms (e.g. fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal imaging

    • Moderate illness: individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SaO2) >93% on room air at sea level

    • Severe illness: individuals who have respiratory frequency >30 breaths per minute, SaO2 <93% on room air at sea level, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300, or lung infiltrates >50%

    • Critical illness: individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction

HISTORY

  • Many patients with COVID-19 have mild illness or no symptoms; some "asymptomatic test-positive cases" have been found to be pre-symptomatic, testing positive before onset of symptoms.

  • Of patients who develop symptoms, 95% will have symptoms appear within 12 days of exposure.

  • Common symptoms include: fever, shortness of breath/difficulty breathing, cough, shaking/chills, muscle pain, headache, sore throat, abdominal pain/diarrhea, and new loss (or alteration) of taste and smell (56).

  • Modeling data to discern influenza from COVID-19 found influenza initially presents as cough. COVID-19 often begins with fever, followed by URI symptoms, then upper GI and finally lower GI symptoms (57). 

  • Gastrointestinal symptoms (i.e. anorexia and diarrhea), loss of smell, taste, and fever were 99% specific for COVID-19 (a highly specific test, when positive) (58).

  • Most symptomatic cases mount a fever >38°C/100.4°F.

  • Some patients with severe COVID-19 disease who presented initially with milder illness (and seeming improvement in the first week), went on to develop abrupt pulmonary and systemic decompression theorized to be due to "cytokine storm."

  • Activate EMS if any of the following are present:

    • Extreme difficulty breathing (cannot talk without gasping for air)

    • Blue-colored lips or face

    • Severe or persistent pain or pressure in the chest

    • Severe constant dizziness or lightheadedness

    • Acting confused or unable to wake up

    • Slurred speech (new or worsening)

    • New onset seizure or seizures that will not stop

    • Painful red or purple lesions on fingers or toes in the winter (anecdotal)

ALERT

Risk factors for progression to acute respiratory distress syndrome (ARDS):

  • Age >65 years, neutrophilia, and organ or coagulation dysfunction (59)

  • Chronic lung disease, immunocompromise, obesity (60)

  • Hypertension and diabetes (61)

 

PHYSICAL EXAM

  • Mild-to-severe respiratory illness with fever, cough, dyspnea, and chest discomfort

  • Wheeze and rales are not typically found

  • Hypoxia. Pulse oximetry may reveal dramatic, relatively asymptomatic hypoxemia. Hypoxemia may be an early diagnostic clue of COVID-19 (62).

  • Livedoid and necrotic skin eruptions (63)

DIFFERENTIAL DIAGNOSIS

Influenza, other virally-mediated respiratory illness 
  • Influenza and COVID-19 infection share the following characteristics:

    • Fever or feeling feverish/chills

    • Cough

    • Shortness of breath or difficulty breathing

    • Fatigue (tiredness)

    • Sore throat

    • Runny or stuffy nose

    • Muscle pain or body aches

    • Headache

    • Vomiting and diarrhea; more common in children than adults

  • The single factor that distinguishes COVID-19 from influenza is the lose of sensation of taste and smell (seen in up to 60% of patients based upon observational data from Italy) (64).

DIAGNOSTIC TESTS & INTERPRETATION

Initial Tests (lab, imaging)

  • Priorities for testing include:

    • PRIORITY 1: Healthcare facility workers with symptoms

    • PRIORITY 2: Patients in long-term care facilities with symptoms, patients 65 years of age and older with symptoms, patients with underlying conditions with symptoms, first responders with symptoms

    • PRIORITY 3 as resources allow: critical infrastructure workers, individuals who do not meet any of the above categories with symptoms, healthcare facility workers and first responders, individuals with mild symptoms in communities experiencing high numbers of COVID-19 hospitalizations (65).

  • Testing options: molecular tests detect the SARS-CoV-2 viral RNA from nasopharyngeal and other respiratory specimens. Serological tests detect the presence of antibodies (IgG;IgM) produced by the immune system in response to the infection.

    • Molecular test: CDC 2019-Novel Coronavirus (2019-nCoV) RT-PCR diagnostic panel (specimens refrigerated at 2-8ºC)

      • Intended for use with upper and lower respiratory specimens collected only from persons who meet CDC criteria for COVID-19 testing

      • Nasopharyngeal swab AND oropharyngeal swab (use only synthetic fiber swabs with plastic shafts with a viral transport media), or oral swabbing AND nasal swabbing on a single swab

      • Systematic review of RT-PCR testing finds false negative rates of between 2% and 29% (sensitivity of 71% and specificity of 95%) for nasopharyngeal swab. As this test is highly specific, when positive, it rules IN disease. However, when negative, repeat testing should be obtained as it does not rule out disease (66).

        • The Abbott ID NOW point-of-care test for SARS-CoV-2 has been recently called into question, as it may have a high false-negative result; if positive, it can be assumed to be a true positive, but if negative, consider further testing (67).

    • Serologic testing for an immune response is best used to determine who has been exposed. Serologic tests are not designed to be diagnostic of infection, but rather as evidence of exposure.

      • The U.S. Food & Drug Administration (FDA) has stated that these tests should only be used by institutions collecting convalescent sera and not for diagnostic purposes (68).

      • Based upon a Cochrane Systematic Review, testing for IgG and IgM antibodies against SARS-CoV-2 found a sensitivity of just 30% during the first week of symptoms, increasing to 91% by the third week. Specificity was above 98%, a high rate of false negatives, but a positive is highly likely to be a true positive (69).

  • PCR tests are more accurate (have a higher sensitivity) but take longer. Antigen tests have a lower sensitivity but a high specificity (70).

    • FDA issued a statement on rapid antigen testing having higher rates of false positives, especially if the end user does not store the testing components properly and readings the outcomes not at the test's specified time (too soon after the required time).

  • Pooled testing: the FDA has issued an emergency use authorization for the Quest Diagnostics RT-PCR test for SARS-CoV-2 to be used with swab specimens pooled from up to four patients. The rationale for pooled testing is if the pool tests negative, all patients are considered negative; if it's positive, each individual sample needs to be retested, saving time and supplies (71).

  • Obtain coagulation studies and d-dimer on admission and closely monitor for signs consistent with deep vein thrombosis. Venous thrombosis has been found in over 70% of critically ill patients within 48 hours of hospitalization, despite being on anti-thrombosis prophylaxis since admission (72).

  • Deep vein thrombosis almost tripled mortality (73).

Follow-Up Tests & Special Considerations

ALERT
  • For worsening symptoms: chest X-ray, confirmatory CT scan. Early CT findings include peripheral ground glass opacities (GGO) which can progress to bilateral or multifocal pneumonia

  • Consider LDH, hsCRP and d-dimer as a baseline.

  • For patients whose symptoms progress from mild to moderate, severe or critical, consider obtaining and monitoring d-dimer, prothrombin time, platelet counts, fibrinogen.

    • Increased d-dimers are reported in patients with severe illness and may predict mortality.

    • A tripling of the d-dimer may predict worsening clinical course.

    • Fibrinogen should be monitored to predict disseminated intravascular coagulation (DIC); nonsurvivors with severe illness have developed DIC around day 4; significant worsening in those parameters at days 10 and 14 was also reported.

    • Prophylactic low-molecular weight heparin (unless there is active bleeding or a platelet count of <25x109/L) is suggested with the hope of lowering the impact of the septic-like coagulopathy and protecting against venous thromboembolism.

 

TREATMENT

GENERAL MEASURES

  • Resources for healthcare providers from the U.S. CDC can be found at: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index/html.

  • Current data on critical care can be found at: https://journals.lww.com/ccmjournal/Fulltext/2020/06000/Surviving_Sepsis_Campaign__Guidelines_on_the.29.aspx.

  • Continuously updated guidelines from NIH based on severity of illness: https://www.covid19treatmentguidelines.nih.gov/whats-new/

  • Hospital infection prevention and control measures include use of personal protective equipment (PPE) for aerosol, droplet, and contact precautions (e.g. masks, face shields, gloves, gowns), including eye protection (e.g. face shields or goggles) and single-patient dedicated medical equipment (e.g. stethoscopes, blood pressure cuffs, thermometers). Limit the number of individuals and providers entering the room of a patient with COVID-19.

  • If necessary, hospitalized patients with confirmed COVID-19 may be cohorted in the same room. Airborne infection isolation rooms (AIIRs) should be used for patients who will be undergoing any aerosol-generating procedures. During the procedures, all staff should wear N95 respirators or powered, air-purifying respirators (PAPRs).

  • Respiratory/ventilatory support (recommendations of NIH updated June 2020):

    • For adults with COVID-19 and acute hypoxemic respiratory failure despite conventional oxygen therapy, the Panel recommends high-flow nasal cannula (HFNC) oxygen over noninvasive positive pressure ventilation (NIPPV).

    • For patients with persistent hypoxemia despite increasing supplemental oxygen requirements in whom endotracheal intubation is not otherwise indicated, the Panel recommends considering a trial of awake prone positioning to improve oxygenation.

    • The Panel recommends against using awake prone positioning as a rescue therapy for refractory hypoxemia to avoid intubation in patients who otherwise require intubation and mechanical ventilation.

    • For mechanically ventilated adults with COVID-19 and ARDS, the Panel recommends using low tidal volume (VT) ventilation (VT 4-8 mL/kg of predicted body weight) over higher tidal volumes (VT >8 mL/kg) (AI).

    • For mechanically ventilated adults with COVID-19 and refractory hypoxemia despite optimized ventilation, the Panel recommends prone ventilation for 12 to 16 hours per day over no prone ventilation.

ALERT
  • Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can experience a range of clinical manifestations, from no symptoms to critical illness. Currently, no FDA-approved drugs exist to specifically treat patients with COVID-19.

  • For asymptomatic, presymptomatic or those patients with minimal respiratory symptoms: the proportion of infected individuals who remain asymptomatic or minimally symptomatic is high, and likely significantly exceeds the proportion of symptomatic patients. For this population, the NIH Guideline Update of October 10, 2020 recommends AGAINST use of any anti-viral agent and AGAINST use of any steroid, including dexamethasone (74).

  • Asymptomatic persons testing positive for SARS-CoV-2 should self-isolate. If they remain asymptomatic, they can discontinue isolation 10 days after the date of their first positive SARS-CoV-2 test. Individuals who become symptomatic should contact their healthcare provider for further guidance. Healthcare workers who test positive and are asymptomatic may obtain additional guidance from their occupational health service. See the CDC COVID-19 website for detailed information. No additional laboratory testing is currently recommended.

  • Mild illness

    • Mild illness can be defined by various signs and symptoms (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath or dyspnea or abnormal imaging. Most mildly ill patients can be managed at home through telemedicine or remote visits.

    • Closely monitor all patients with symptomatic COVID-19 and risk factors for severe disease as some may rapidly progress.

    • No specific laboratory evaluations are indicated in otherwise healthy patients with mild COVID-19 disease.

    • There are insufficient data to recommend any specific medication or immunomodulatory therapies for patients with COVID-19 with mild illness.

  • Moderate illness (hospitalized requiring supplemental oxygen but not via high-flow device)

    • Moderate COVID-19 illness is defined by evidence of lower respiratory disease by clinical assessment, imaging with SpO2 >93% on room air at sea level. Given that pulmonary disease can rapidly progress, patients with moderate COVID-19 should be admitted for close observation. If bacterial pneumonia or sepsis is suspected, administer empiric antibiotic treatment for community-acquired pneumonia, reevaluate regularly. Deescalate or stop antibiotics when there is no evidence of bacterial infection.

    • Treatment for hospitalized patients who require supplemental oxygen but not through a high-flow device. Noninvasive ventilation, invasive ventilation, or ECMO. The NIH October 10, 2020 guidelines recommend:

  • Treatment for moderate to severe illness (hospitalized patients who require supplemental oxygen via high-flow device or via non-mechanical ventilation)

    • Remdesivir 200 mg IV for one day, followed by remdesivir 100 mg IV once a day for 4 days or until hospital discharge, whichever comes first, OR

    • Remdesivir as above plus dexamethasone 6 mg IV or PO daily for up to 10 days or until hospital discharge, whichever comes first

    • If remdesivir cannot be used, dexamethasone alone may be used (74).

  • Severe illness

    • Patients with COVID-19 are considered to have severe illness if they have SpO2 ≤93% on room air at sea level, respiratory rate >30, PaO2/FiO2 <300, or lung infiltrates in over 50% of lung fields. These patients may experience rapid clinical deterioration and will likely need to undergo aerosol-generating procedures. They should be admitted to the hospital and placed in AIIRs, if available. Administer oxygen therapy immediately using high-flow oxygen.

    • If secondary bacterial pneumonia or sepsis is suspected, administer empiric antibiotics, reevaluate regularly, and if there is no evidence of bacterial infection, deescalate or stop antibiotics.

    • Treatment for severe illness:

  • Critical illness

    • COVID-19 is primarily a pulmonary disease. Severe cases may be associated with ARDS, septic shock that may represent virus-induced distributive shock, cardiac dysfunction, elevations in multiple inflammatory cytokines that provoke a cytokine storm, and/or exacerbation of underlying comorbidities. In addition to pulmonary disease, patients with COVID-19 may also experience cardiac, hepatic, renal, and central nervous system disease.

    • Since patients with critical illness are likely to undergo aerosol-generating procedures, they should be placed in AIIRs when available.

    • Most of the recommendations for the management of critically ill patients with COVID-19 are extrapolated from experience with other life-threatening infections. Currently, there is limited information to suggest that the critical care management of patients with COVID-19 should differ substantially from the management of other critically ill patients, although special precautions to prevent environmental contamination by SARS-CoV-2 is warranted.

    • As with any patient in the intensive care unit (ICU), successful clinical management of a patient with COVID-19 depends on attention to the primary process leading to the ICU admission, but also to other comorbidities and nosocomial complications.

    • Proning is useful to reduce need for intubation and in intubated patients to reduce O2 requirement, as noted above.

    • Treatment for critical illness:

 

MEDICATION

  • Oxygen

  • Hydration

  • Acetaminophen (max is 1,000 mg every 6 hours in patient without liver disease) given around the clock to address fever

  • Outpatient: Bamlanivimab, a monoclonal antibody given emergency authorization by the FDA, is indicated for SARS-CoV-2 positive patients aged 12 years or older who weigh at least 40 kg AND are at increased risk (adults 65 and older and patients with certain medical comorbidities) for progression to severe COVID-19 or hospitalization. A randomized, placebo-controlled, phase 2 trial of bamlanivimab interim analysis at 28 days found the incidence of hospitalization or emergency department visit was ~3% in bamlanivimab recipients vs. 10% in the placebo arm.  Treatment should be given as soon as possible and within 10 days of symptom onset. It is NOT authorized for hospitalized patients or those who require oxygen therapy (75).

  • Hospitalized adults with COVID-19 should receive VTE prophylaxis per the standard of care for other hospitalized adults (unless there is active bleeding or a platelet count of <25x109/L) is suggested with the hope of lowering the impact of the septic-like coagulopathy and protecting against venous thromboembolism (https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy-antithrombotic-therapy).

  • Those who develop thromboembolism should be managed with therapeutic doses of anticoagulant therapy as per the standard of care for patients without COVID-19.

  • Use of NSAIDs in addition to acetaminophen is controversial; there is no data showing they are problematic, but a theoretical rationale should make their use only if acetaminophen is inadequate to maintain fever control.

ALERT

Use of chloroquine or hydroxychloroquine, either alone or with azithromycin, should NOT be prescribed for outpatients. Experimental protocols with sicker inpatients are underway. Use in outpatients may well cause harm and decrease availability of medication for patients with known need (e.g., rheumatoid arthritis, systemic lupus erythematosus).

 
ALERT

Patients who have worsening symptoms with declining function should be admitted to the hospital for observation for further deterioration.

 

First Line

  • Antibiotics: for severely and critically ill patients, some start empiric broad-spectrum antimicrobial therapy for COVID-19 patients; for patients in shock, empiric broad-spectrum antimicrobial therapy is the standard of care. Antibiotic stewardship is critical to avoid reflexive or continued courses of antibiotics (https://www.covid19treatmentguidelines.nih.gov/critical-care/general-considerations/).

  • Dexamethasone: dexamethasone (at a dose of 6 mg per day for up to 10 days) for the treatment of COVID-19 in patients who are mechanically ventilated (AI) and in patients who require supplemental oxygen but who are not mechanically ventilated (NIH Guideline). Dexamethasone improves 28-day mortality compared to placebo in patients requiring IMV (NNT=8.5) and those patients requiring oxygen therapy (NNT=29). Dexamethasone is not recommended for milder disease and may be harmful (76).

  • WHO meta-analysis on the use of steroids on severely ill COVID-19 patients found the 28-day mortality (the primary outcome) was significantly lower in the steroids group (222/678; 32.7%) than in the control group (425/1025; 41.5%); the odds ratio was 0.66 (77).

  • Remdesivir: the NIH Panel recommends administering the investigational antiviral agent remdesivir  for 5 days for the treatment of COVID-19 in hospitalized patients with SpO2 ≤94% on room air (at sea level) or those who require supplemental oxygen, and for patients who are on mechanical ventilation or ECMO. Initial data finds recovery is shortened with remdesivir but no mortality benefit has been shown (78). In late August 2020, the US FDA gave emergency authorization despite the drug's limited data or mortality benefit

    • A study of 600 patients with COVID-19 who did not require oxygen randomized to either a 5- or 10-day course of remdesivir or standard care. At day 11, 5 days of remdesivir  improved survival vs. standard care. There was no difference for the 10-day group, but by day 14, both treatment groups were significantly better than standard care (79).

    • A recent industry sponsored trial of 584 patients with moderate COVID-19 (defined as hospitalized with evidence of COVID-19 pneumonia but no hypoxia) were randomized to 10 days of RDV, 5 days of RDV, or standard care with outcomes measured at “Day 11” on a 7-point ordinal scale. Those in the 5 day arm had significantly better scores than those in the 10 day arm or control groups, but in all groups there was no significant difference in time to recovery, time to improvement in clinical status, or death at 28 days (79).

    • The SOLIDARITY trial (>11,000 hospitalized patients with COVID-19 who were not on mechanical ventilation or ECMO) randomized to study medications that were locally available (lopinavir/ritonavir, hydroxychloroquine, interferon beta-1a, or remdesivir) found no benefit to any of the medications on mortality (80).

      • Despite the SOLIDARITY data, the U.S. FDA voted to approve remdesivir for use in COVID-19 patients who require hospitalization and are at least 40 kg in weight (81).

  • ECMO: Venovenous extracorporeal membrane oxygenation (ECMO) has some potential for COVID-19 patients with severe respiratory failure despite receiving invasive mechanical ventilation (82).

  • Famotidine:

    • A retrospective, propensity matched trial of ~900 SAR-CoV-2 patients admitted to the hospital found treatment with famotidine decreased in-hospital mortality (OR = 0.37; CI 0.16 – 0.86, p = 0.021); combined death or intubation (OR = 0.47; CI 0.23 – 0.96, p = 0.040) and lower serum markers of inflammation (83).

    • A post hoc analysis of in-hospital use of famotidine did not find a mortality benefit compared to non-use. It was unclear if pre-hospital famotidine use had any influence of COVID-19 mortality (84).

  • Aspirin: A retrospective, observational cohort study of patients receiving aspirin within 24 hours of admission or those taking aspirin 7 days prior to admission (believed to be for ASCVD prophylaxis) found, after adjusting for confounding variables, aspirin use was associated with decreased risk of mechanical ventilation (adjusted HR 0.56, 95% CI 0.37-0.85, p=0.007), ICU admission (adjusted HR 0.57, 95% CI 0.38-0.85, p=0.005), and in-hospital mortality (adjusted HR 0.53, 95% CI 0.31-0.90, p=0.02). There were no differences in major bleeding (p=0.69) or overt thrombosis (p=0.82) between aspirin users and non-aspirin users. Aspirin was started at time of admission (IQR 0-1 days), median dose was 81 mg (IQR 81-81 mg), and median treatment duration was 6 days (IQR 3-12 days). Despite the improved outcomes, patients who received aspirin had significantly higher pre-COVID rates of hypertension, diabetes mellitus, coronary artery disease, and renal disease (85).

  • A large number of medications remain under investigation: antivirals, immunomodulatory medications (e.g., Regeneron recently stopped trial of polyclonal antibodies in those patients requiring high-flow oxygen or ventilation due to an "unfavorable risk/benefit profile") cytokine inhibitors, and other classes. The following medications are among the better-known examples of medications under investigation:

    • Nebulized interferon beta-1: in a study of ~100 patients hospitalized with COVID-19, nebulized interferon beta-1 x 14 days resulted in clinical improvement at beta-1a is associated with higher odds of clinical improvement at 15 and 28 days (86).

    • Lopinavir-Ritonavir (not likely to prove effective)

    • Hydroxychloroquine /chloroquine (not likely to prove effective in prophylaxis or in treatment) with or without azithromycin, and maybe harmful (prolonged QT and increased death)

      • Systematic review of hydroxychloroquine treatment of hospitalized COVID-19 patients did not reduce risk of death or illness vs. standard care. High dose regimens or when combined with macrolides may be associated with harm. Postexposure prophylaxis may not reduce the rate of infection, but the quality of evidence is low (87).

      • In outpatients with ≤4 days of COVID-19 symptoms (with either laboratory-confirmed SARS-CoV-2 infection or epidemiological link to a confirmed COVID-19 case), a randomized clinical trial studied 5 days of hydroxychloroquine or placebo. The treatment and placebo group outcomes were found to not differ in symptom-severity change, hospitalizations, or deaths. But, the hydroxychloroquine recipients had significantly more adverse effects (mostly GI) compared to placebo recipients (43% vs. 22%; number needed to harm, 5) (88).

    • In patients with type 2 diabetes hospitalized with COVID-19, the addition of the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin to insulin treatment was found to lower ICU admission, need for mechanical ventilation use, and mortality risk  (89).

    • Interferons

    • Monoclonal antibodies

    • Convalescent plasma (sera): Promising benefit has been reported in critically ill patients, but there is still very limited data on its benefit (90). 

      • FDA has granted emergency authorization for use in patients critically ill with COVID-19. This is based on data from the Mayo Clinic of 35,000 patients hospitalized with COVID-19. Outcomes found the 7-day mortality was 8.7% in those transfused within 3 days of diagnosis vs. 11.9% if transfused 4 or more days later. At 30-days, mortality was 21.6% vs. 26.7%, p<0.0001.  It also found transfusions with higher IgG levels (18.45 S/Co) vs. low IgG plasma had lower mortality at 7 and 30 days. Pooled relative risk of mortality with high antibody levels was 0.65 [0.47-0.92] at 7 days and 0.77 [0.63-0.94] at 30 days. This study did not contain a placebo arm and was published without peer review (91).

      • In late August 2020, the NIH cautioned against emergency approval, saying that the data were not strong enough. NIH considers data to be insufficient to recommend for or against convalescent plasma.

      • A randomized, controlled study of almost 500 patients in India evaluated convalescent plasma vs. none in addition to the standard of care and found progression to severe disease or all-cause mortality within 28 days was ~18% in all patients, regardless of receiving plasma. Those in the intervention arm did have a higher conversion to a negative SARS-CoV-2 RNA test result, demonstrating efficacy of clearing the virus, but with no impact on clinical outcomes (92).

      • An open-label RCT of convalescent plasma for patients with moderate to severe pulmonary symptoms in COVID-19 across India on progression to severe disease or all-cause mortality at 28 days found no lower risk of severe disease or mortality (92).

ALERT

If you have a patient who has recovered from COVID-19, and is interested in donating plasma, go to https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/donate-covid-19-plasma.

 

ISSUES FOR REFERRAL

For any patient meeting criteria for evaluation for COVID-19, clinicians are encouraged to contact and collaborate with their state or local health department. 

SURGERY/OTHER PROCEDURES

Depending on local case rates, elective procedures and surgeries may be postponed. COVID-19 testing is required pre-operatively for elective and emergent procedures. 

ADMISSION, INPATIENT, AND NURSING CONSIDERATIONS

  • Review NIH Guidelines as above.

  • Any patient who has had a potential exposure and is ill should NOT enter an ambulatory healthcare facility; remain at home to allow quarantine. Maintain contact via telephone or telemedicine methods.

  • CDC recommends for patients aged ≥2 years to call 911 if any of the following are present:

    • Extreme difficulty breathing (cannot talk without gasping for air)

    • Blue-colored lips or face

    • Severe or persistent pain or pressure in the chest

    • Severe constant dizziness or lightheadedness

    • Acting confused or unable to wake up

    • Slurred speech (new or worsening)

    • New onset seizure or seizures that will not stop

ONGOING CARE

  • Anxiety of patients infected with coronavirus and their close contacts, along with the general population, remains high. Reassure those who test positive to monitor their symptoms and to contact you if they worsen.

  • CDC services include phone and text consultations for these issues at:

  • Depression prevalence in the U.S. has tripled during the pandemic compared to 2017–2018 data. Approximately 1,400 adults surveyed about depressive symptoms in spring of 2020 were compared to ~5,000 adults from the National Health and Nutrition Examination Survey in 2017–2018. In the pre-pandemic cohort, 9% had depressive symptoms vs. 28% during the pandemic; this included a 7-fold increase in risk of severe depression. Populations currently at greatest risk are those with the lowest incomes, where almost 50% had reported depressive symptoms during the pandemic (93).

  • For the general population, offer support and tele-counseling sessions; some therapists are offering this service without charge.

  • Limit anxiolytics as they can compromise symptom recognition in patients who may become ill from any severe illness or infection.

  • Consider cardiac magnetic resonance imaging (MRI) in college athletes before returning to play. A small study of 26 college athletes who tested COVID-19 positive (45% without symptoms) were screened for cardiac manifestations by cardiac MRI after recovery. All had normal electrocardiograms, echocardiograms, and troponin levels. Fifteen percent (all male) had findings consistent with myocarditis with mild (slight shortness of breath) or no symptoms (94).

FOLLOW-UP RECOMMENDATIONS

  • General population: On May 22, 2020, the CDC issued new guidelines on management of COVID-19 patients.

    • People with COVID-19 who experienced symptoms and isolated at home can leave home under the following conditions:

      • If there has not been a test to determine persistent infection, people can leave home after these three things have happened:

        • Afebrile for at least 72 hours (that is three full days of no fever without the use of medicine that reduces fevers) AND

        • Other symptoms have improved (for example, when your cough or shortness of breath have improved) AND

        • At least 10 days have passed since symptoms first appeared

      • If there has been a test to determine persistent infection people can leave home after these three things have happened:

        • Afebrile (without the use of medicine that reduces fevers) AND

        • Other symptoms have improved (for example, when cough or shortness of breath have improved) AND

        • There have been two negative tests in a row, at least 24 hours apart.

    • People who DID NOT have COVID-19 symptoms, but tested positive and have isolated at home can leave home under the following conditions:

      • If there has not been a test to determine persistent infection, people can leave home after these two things have happened:

        • At least 10 days have passed since the date of the first positive test AND

        • Symptoms have not appeared (no cough or shortness of breath) since the test

      • If there has been a test to determine persistent infection, people can leave home after:

        • There have been two negative tests in a row, at least 24 hours apart.

    • Note: if you develop symptoms, follow guidance above for people with COVID-19 symptoms (95).

  • Healthcare workers: On April 30, 2020, the CDC offered the following Return to Work guidelines, "Return to Work Criteria for HCP with Suspected or Confirmed COVID-19."

    • Symptomatic HCP with suspected or confirmed COVID-19

      • Either strategy is acceptable depending on local circumstances

        • Symptom-based strategy. Exclude from work until:

          • At least 3 days (72 hours) have passed since recovery defined as resolution of fever without the use of fever-reducing medications and improvement in respiratory symptoms (e.g., cough, shortness of breath); and,

          • At least 10 days have passed since symptoms first appeared

        • Test-based strategy. Exclude from work until:

          • Resolution of fever without the use of fever-reducing medications, and

          • Improvement in respiratory symptoms (e.g., cough, shortness of breath), and

          • Negative results of an FDA Emergency Use Authorized COVID-19 molecular assay for detection of SARS-CoV-2 RNA from at least two consecutive respiratory specimens collected ≥24 hours apart (total of two negative specimens). See Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for 2019 Novel Coronavirus (2019-nCoV). Of note, there have been reports of prolonged detection of RNA without direct correlation to recovery of live, infectious virus from viral culture.

    • HCP with laboratory-confirmed COVID-19 who have not had any symptoms

      • Either strategy is acceptable depending on local circumstances

        • Time-based strategy. Exclude from work until:

          • 10 days have passed since the date of their first positive COVID-19 test assuming they have not developed symptoms since their positive test. If they develop symptoms, then the symptom-based or test-based strategy should be used. Note, because symptoms cannot be used to gauge where these individuals are in the course of their illness, it is possible that the duration of viral shedding could be longer or shorter than 10 days after their first positive test.

        • Test-based strategy. Exclude from work until:

          • Negative results of an FDA Emergency Use Authorized COVID-19 molecular assay for detection of SARS-CoV-2 RNA from at least two consecutive respiratory specimens collected ≥24 hours apart (total of two negative specimens). Note, because of the absence of symptoms, it is not possible to gauge where these individuals are in the course of their illness. There have been reports of prolonged detection of RNA without direct correlation to viral culture.

    • Note that detecting viral RNA via PCR does not necessarily mean that infectious virus is present.

    • Consider consulting with local infectious disease experts when making return to work decisions for individuals who might remain infectious longer than 10 days (e.g., severely immunocompromised).

    • If HCP had COVID-19 ruled out and have an alternate diagnosis (e.g., tested positive for influenza), criteria for return to work should be based on that diagnosis.

ALERT

The American Academy of Pediatrics recommends that youth athletes with COVID-19 who have had moderate symptoms (e.g., prolonged fever), cardiac symptoms, or other concerning findings should undergo electrocardiography prior to returning to play sports and may need pediatric cardiology for clearance to return to sports. Serum enzyme levels and EKG findings that are normal should not be considered adequate for return unless there are no symptoms, especially chest pain/pressure or dyspnea as MRI findings show a subset of young athletes have a persistent myocarditis that is not identified on blood or EKG testing. Any abnormal cardiac finding must return to normal before the athlete returns to play (96).

 

Patient Monitoring

Encourage those who test positive to monitor their breathing, and if they develop dyspnea with activity or at rest, to contact their PCP or be seen in an emergency department. 

PATIENT EDUCATION

  • Frequently clean hands by using alcohol-based hand rub or soap and water.

  • When coughing and sneezing, cover mouth and nose with flexed elbow or tissue. Throw tissue away immediately and wash hands.

  • Avoid close contact with anyone who has fever and cough.

  • If you have fever, cough, and difficulty breathing, seek medical care early.

  • Wear a face mask when in public and unable to remain at least 6 feet from others.

  • For patients on PPIs, consider switching to an H2RA (famotidine 20 mg BID or nizatidine 150 mg BID).

  • As vitamin D deficiency increases risk of COVID-19 infection and severity of disease, consider recommending to patients to take 2–4,000 IU vitamin D per day. While not proven to be protective, vitamin d deficiency is common, and there is little risk at this dose (https://www.health.com/nutrition/vitamins-supplements/dr-fauci-vitamin-c-and-d).

  • Urge patients NOT to ingest disinfectants and "light" therapies for prevention or treatment of COVID-19.

  • Medications and other therapies written for the general public can be found at https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html.

  • Urge patients NOT to seek out hydroxychloroquine for prevention or treatment of COVID-19.

  • Patients with COVID-19 should continue taking their angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs).

    • A statement from the American Heart Association, the Heart Failure Society of America, and the American College of Cardiology (97) initially supported this position and 3 recent studies have found no worsening of outcomes of COVID-19 infections based upon anti-hypertensive agent being taken (98). A recent single-center case of 362 patients hospitalized with COVID-19 infection found no difference in severity of the disease, complications, and risk of death in those who were taking ACEIs/ARBs compared with those not on these medications (99).

  • Patients with mild illness should self-isolate/quarantine until symptoms have completely resolved for 72 hours minimum.

  • Patient resource on home care: https://www.cdc.gov/coronavirus/2019-ncov/downloads/10Things.pdf

  • All should try to get 30 minutes of exercise per day. A survey study of ~370 adults' health and wellbeing after one month of confinement due to COVID-19 in China found those who stopped working reported worse mental and physical health conditions. This was mitigated by exercise for ≤30 minutes per day (100).

PROGNOSIS

  • 80% of patients have mild, self-resolving illness requiring no intervention.

  • Observational data from Indiana found the infection fatality ratio of 0.26% of those not institutionalized aged 12 and older. Higher infection fatality ratios were seen in those aged 60 and older (1.71%) (this does not include those in nursing homes, rehabilitation centers, etc.) and among non-whites (0.59%). The infection fatality ratio of those aged 65 and older for the seasonal influenza is ~0.8% (101).

  • U.S. mortality compared to other western countries: mortality data through September 19, 2020 found the mortality rate in the U.S. was 60.3/100,000 compared to Australia (3.3 deaths per 100,000), Canada (24.6 per 100,000), Italy (59.1/100,000), and Belgium (86.8 per 100,000).

    • Outcomes if the U.S. death rates were comparable to other similar countries:

      • If like Australia, the U.S. would have had 187,661 fewer COVID-19 deaths.

      • If like Canada, 117,622 fewer deaths

  • CDC data on prognosis in those under age 20 years found:

    • ~70% of deaths occurred in those aged 10 through 20 years, 20% aged 1 through 9, and 10% under 1 year with Black and Latino youth accounting for ~75% of those who died.

    • Predisposing conditions of those who died include chronic lung disease (mostly asthma), obesity, neurologic/developmental conditions, and cardiovascular syndromes (102).

  • Duration of immunity from infection is unknown. While reinfection has occurred with other coronaviruses, they typically occur months to years after the initial infection (103).

  • Immunity persistence is unclear; from a study of 82 confirmed and 58 probably cases of COVID-19 from China, the median duration of IgM detection was 5 days (interquartile range, 3-6), while IgG was detected at a median of 14 days (interquartile 10-18) after symptom onset (104).

  • A small U.S. study followed antibody levels after mild COVID-19 in 34 patients with mild COVID-19 using serial anti-SARS-CoV-2 receptor binding domain IgG levels. The estimated mean IgG half-life was 36 days (105).

  • There remains conflicting data on persistence of antibody response in those already infected with the virus, with some showing loss of antibodies within a few weeks, while others show persistence up to 120 days after infection (106).

  • U.S. cohort data tracked estimated excess deaths in the U.S. between March 1 and May 30, 2020, and compared it to data from January 5, 2015 through January 25, 2020. During these three months in 2020, there were 780,975 total deaths; 122,300 more deaths than expected from previous years, with COVID-19 accounting for 78% of these deaths, implying significant under-reporting (107).

  • Laboratory findings that correlate with an increased mortality include leukocytosis with lymphopenia, and highly-elevated LFTs, creatinine, lactate dehydrogenase, troponin, N-terminal-pro-brain natriuretic peptide, and d-dimer compared to those who recovered.

  • Morbidities that correlate with death include acute respiratory distress syndrome, sepsis, acute cardiac injury, heart failure, acute kidney injury, and encephalopathy (108).

  • UK cohort data of neurologic outcomes of COVID infection included cerebrovascular events and mental status changes (encephalopathy, encephalitis) (109).

  • Postinfection neuropsychiatric disorders were studied in a systematic review and meta-analysis of 65 studies and 7 preprints from multiple countries.

    • From the 25 studies of SARS and MERS:

      • Insomnia (41% of patients), anxiety (36%), concentration impairment (38%), memory difficulties (34%), depression (33%), and confusion (27%)

      • After the infection (60 days to 12 years), 40 studies found traumatic memories (30%), emotional lability (24%), memory impairment (19%), fatigue (19%), irritability (13%), anxiety (12%), insomnia (12%), pressured speech (12%), euphoria (11%), and depression (10%) with a prevalence of 15% for depression and for anxiety, and 32% for post-traumatic stress disorder (PTSD).

    • Of the 12 COVID-19 studies:

      • Findings included acute-phase delirium, agitation, and alterations in consciousness, with some cognitive dysfunction after hospitalization (110).

  • An Italian cohort study of 143 patients hospitalized for COVID-19 evaluated symptoms at a mean of 60 days after symptom onset and 36 days after hospital discharge. Mean age of 56.5 years, 37% were women, and the mean length of hospitalization was 13.5 days. During hospitalization, 73% had interstitial pneumonia, 15% required noninvasive ventilation, and 5% received mechanical ventilation. Participants were virus-free by PCR. Only 13% of participants reported being symptom-free but 55% had 3 or more symptoms. The most common persistent symptoms were fatigue 53%, dyspnea 43%, joint pain 27%, and chest pain 22%. Compared to pre-COVID-19 infection, 44% reported their quality of life was ≥10 points lower on a scale of 0 (worst health) to 100 (best health) (111).

REFERENCES

1
CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426.
2
Reuters. Rare syndrome tied to COVID-19 kills three children in New York, Cuomo says. https://www.reuters.com/article/us-health-coronavirus-usa-ny-idUSKBN22L0OF. Accessed May 11, 2020.
3
Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383(4):334-346.
4
Centers for Disease Control and Prevention. Coronavirus Disease 2019: Racial & Ethnic Minority Groups. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html. Accessed July 20, 2020.
5
Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). Cases, Data & Surveillance: Commercial Laboratory Seroprevalence Survey Data. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html. Accessed August 12, 2020.
6
American Academy of Pediatrics. Children and COVID-19: State-Level Data Report. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. Accessed August 12, 2020.
7
Young BE, Fong SW, Chan YH, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study [published online ahead of print, 2020 Aug 18]. Lancet. 2020;S0140-6736(20)31757-8.
8
World Health Organization. Origin of SARS-CoV-2. https://apps.who.int/iris/bitstream/handle/10665/332197/WHO-2019-nCoV-FAQ-Virus_origin-2020.1-eng.pdf. Accessed July 20, 2020.
9
Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172(9):577-582.
10
Sakurai A, Sasaki T, Kato S, et al. Natural History of Asymptomatic SARS-CoV-2 Infection [published online ahead of print, 2020 Jun 12]. N Engl J Med. 2020;10.1056/NEJMc2013020.
11
Qin J, You C, Lin Q, et al. Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. Preprint. medRxiv. 2020;2020.03.06.20032417. Published 2020 Mar 10.
12
Watchmaker JM, Goldman DT, Lee JY, et al. Increased Incidence of Acute Pulmonary Embolism in Emergency Department Patients During the COVID-19 Pandemic. Acad Emerg Med. 2020 Oct 5. doi: 10.1111/acem.14148. Epub ahead of print.
13
Colafrancesco S, Alessandri C, Conti F, et al. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? [published online ahead of print, 2020 May 5]. Autoimmun Rev. 2020;102573.
14
He J, Guo Y, Mao R, et al. Proportion of asymptomatic coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis [published online ahead of print, 2020 Jul 21]. J Med Virol. 2020;10.1002/jmv.26326.
15
Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic Dysregulation in COVID-19 Pneumonia is Associated with Respiratory Failure and Coagulopathy [published online ahead of print, 2020 Jul 28]. Circulation. 2020;10.1161/CIRCULATIONAHA.120.048488.
16
Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500.
17
Rottoli M, Bernante P, Belvedere A, et al. How important is obesity as a risk factor for respiratory failure, intensive care admission and death in hospitalised COVID-19 patients? Results from a single Italian centre [published online ahead of print, 2020 Jul 1]. Eur J Endocrinol. 2020;EJE-20-0541.R2.
18
Centers for Disease Control and Prevention. CDC Newsroom: CDC updates, expands list of people at risk of severe COVID-19 illness [press release]. https://www.cdc.gov/media/releases/2020/p0625-update-expands-covid-19.html. Accessed July 20, 2020.
19
Liang W, Liang H, Ou L, et al. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients with COVID-19. JAMA Intern Med. 2020 May 12. [Epub ahead of print]
20
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020 (pre-print posted online July 7, 2020). https://journals.lww.com/ajg/Documents/AJG-20-1811_R1(PUBLISH%20AS%20WEBPART).pdf. Accessed August 4, 2020.
21
Meltzer DO, Best TJ, Zhang H, et al. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open. 2020;3(9):e2019722.
22
Castillo ME, Entrenas Costa LM, Vaquero Barrios JM, et al. "Effect of Calcifediol Treatment and best Available Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study" [published online ahead of print, 2020 Aug 29]. J Steroid Biochem Mol Biol. 2020;105751.
23
Maghbooli Z, Sahraian MA, Ebrahimi M, et al. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection. PLoS One. 2020 Sep 25;15(9):e0239799. 
24
Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 with Respiratory Failure [published online ahead of print, 2020 Jun 17]. N Engl J Med. 2020;10.1056/NEJMoa2020283.
25
Ellington S, Strid P, Tong VT, et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):769-775.
26
Salvatore CM, Han JY, Acker KP, et al. Neonatal management and outcomes during the COVID-19 pandemic: an observation cohort study [published online ahead of print, 2020 Jul 23]. Lancet Child Adolesc Health. 2020;S2352-4642(20)30235-2.
27
Huntley BJF, Huntley ES, Di Mascio D, et al. Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review. Obstet Gynecol. 2020;136(2):303-312.
28
Chambers C, Krogstad P, Bertrand K, et al. Evaluation for SARS-CoV-2 in Breast Milk From 18 Infected Women [published online ahead of print, 2020 Aug 19]. JAMA. 2020;10.1001/jama.2020.15580.
29
Czeisler MÉ, Lane RI, Petrosky E, et al. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057.
30
Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973-1987.
31
Dehning J, Zierenberg J, Spitzner FP, et al. Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions. Science. 2020 May 2015. [Epub ahead of print]
32
Centers for Disease Control and Prevention. Coronavirus Disease: Contact Tracing. https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/contact-tracing.html. Accessed October 26, 2020.  
33
Badr HS, Du H, Marshall M, Dong E, Squire MM, Gardner LM. Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study [published online ahead of print, 2020 Jul 1]. Lancet Infect Dis. 2020;S1473-3099(20)30553-3.
34
Hatoun J, Correa ET, Donahue SMA, et al. Social Distancing for COVID-19 and Diagnoses of Other Infectious Diseases in Children [published online ahead of print, 2020 Sep 2]. Pediatrics. 2020;e2020006460.
35
Bae S, Kim MC, Kim JY, et al. Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2: A Controlled Comparison in 4 Patients. Ann Intern Med. 2020 Apr 6. [Epub ahead of print]
36
Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med. 2020;26(5):676-680. 
37
Centers for Disease Control and Prevention. Coronavirus Disease. Scientific Brief: Community Use of Masks to Control the Spread of SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html. Accessed November 16, 2020.
38
Bhaskar ME, Arun S. SARS-CoV-2 Infection Among Community Health Workers in India Before and After Use of Face Shields [published online ahead of print, 2020 Aug 17]. JAMA. 2020;10.1001/jama.2020.15586.
39
Stutt ROJH, Retkute R, Bradley M, et al. A modelling framework to assess the likely effectiveness of facemasks in combination with ‘lock-down’ in managing the COVID-19 pandemic. Proc R Soc. 476:20200376. Published:10 June 2020.
40
Zhang R, Li Y, Zhang AL, et al. Identifying airborne transmission as the dominant route for the spread of COVID-19. Proc Natl Acad Sci U S A. 2020;117(26):14857-14863.
41
Samannan R, Holt G, Calderon-Candelario R, et al. Effect of Face Masks on Gas Exchange in Healthy Persons and Patients with COPD. Ann Am Thorac Soc. 2020 Oct 2. doi: 10.1513/AnnalsATS.202007-812RL. Epub ahead of print. 
42
Bahl P, Bhattacharjee S, de Silva C, et al. Face coverings and mask to minimise droplet dispersion and aerosolisation: a video case study [published online ahead of print, 2020 Jul 24]. Thorax. 2020;thoraxjnl-2020-215748.
43
Fischer EP, Fischer MC, Grass D, et al. Low-cost measurement of facemask efficacy for filtering expelled droplets during speech. Science Advances. Published Online 07 Aug 2020. DOI: 10.1126/sciadv.abd3083. 
44
Shen Y, Li C, Dong H, et al. Community Outbreak Investigation of SARS-CoV-2 Transmission Among Bus Riders in Eastern China [published online ahead of print, 2020 Sep 1]. JAMA Intern Med. 2020;10.1001/jamainternmed.2020.5225.
45
IHME COVID-19 Forecasting Team. Modeling COVID-19 scenarios for the United States. Nat Med. 2020 Oct 23. doi: 10.1038/s41591-020-1132-9. Epub ahead of print.
46
Ahlawat A, Wiedensohler A. Mishra SK. An Overview on the Role of Relative Humidity in Airborne Transmission of SARS-CoV-2 in Indoor Environments. Aerosol Air Qual. Res. 2020;20:1856–1861.
47
Centers for Disease Control and Prevention. Coronavirus Disease 2019. How It Spreads. https://www.cdc.gov/coronavirus/2019-nc0v-prevent-getting-sick/how-covid-spreads.html. Accessed May 26, 2020.
48
Park YJ, Choe YJ, Park O, et al. Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020 [published online ahead of print, 2020 Jul 16]. Emerg Infect Dis. 2020;26(10):10.3201/eid2610.201315.
49
Luo L, Liu D, Liao X, et al. Contact Settings and Risk for Transmission in 3410 Close Contacts of Patients With COVID-19 in Guangzhou, China: A Prospective Cohort Study [published online ahead of print, 2020 Aug 13]. Ann Intern Med. 2020;10.7326/M20-2671.
50
Luo L, Liu D, Liao X, et al. Contact Settings and Risk for Transmission in 3410 Close Contacts of Patients With COVID-19 in Guangzhou, China: A Prospective Cohort Study. Ann Intern Med. 2020 Aug 13:M20-2671. 
51
Auger KA, Shah SS, Richardson T, et al. Association Between Statewide School Closure and COVID-19 Incidence and Mortality in the US. JAMA. Published online July 29, 2020. doi:10.1001/jama.2020.14348.
52
American Academy of Pediatrics. Clinical Guidance: Critical Updates on COVID-19. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/. Accessed August 18, 2020.
53
The New York Times. Coronavirus Vaccine Tracker. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html. Accessed August 12, 2020.
54
Corey L, Mascola JR, Fauci AS, et al. A strategic approach to COVID-19 vaccine R&D. Science. 2020;368(6494):948-950.
55
Pfizer. Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study [press release]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against. Accessed November 16, 2020.
56
Centers for Disease Control and Prevention. Coronavirus Disease 2019: Symptoms. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed April 27, 2020.
57
Larsen JR, Martin MR, Martin JD, et al. Modeling the Onset of Symptoms of COVID-19. Front Public Health. Published August 13, 2020. doi: 10.3389/fpubh.2020.00473
58
Chen A, Agarwal A, Ravindran N, et al. Are Gastrointestinal Symptoms Specific for COVID-19 Infection? A Prospective Case-Control Study from the United States [published online ahead of print, 2020 May 15]. Gastroenterology. 2020:S0016-5085(20)30664-8.
59
Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1-11. 
60
Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): People Who Are At Higher Risk. https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/people-at-higher-risk.html. Accessed March 28, 2020.
61
World Health Organization. (‎2020)‎. Clinical management of severe acute respiratory infection (‎‎SARI)‎‎ when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization. https://apps.who.int/iris/handle/10665/331446. License: CC BY-NC-SA 3.0 IGO
62
Shah S, Majmudar K, Stein A, et al. Novel use of home pulse oximetry monitoring in COVID-19 patients discharged from the emergency department identifies need for hospitalization. Acad Emerg Med. 2020 Jun 17. [Epub ahead of print]
63
Droesch C, Hoang M, DeSancho M, et al. Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19 [published online ahead of print, 2020 Aug 5]. JAMA Dermatol. 2020;10.1001/jamadermatol.2020.2800.
64
Spinato G, Fabbris C, Polesel J, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA. 2020 May 26;323(20):2089-2090. 
65
Centers for Disease Control and Prevention. Coronavirus Disease 2019: Evaluation & Testing. https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html. Accessed April 9, 2020.
66
Arevalo-Rodriguez O, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. medRxiv 20066787. 2020 10.1101/2020.04.16.20066787.
67
U.S. Food & Drug Administration. FDA News Release. Coronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test. https://www.fda.gov/new-events/press-announcements/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point. Accessed May 18, 2020.
68
U.S. Food & Drug Administration. Important Information on the Use of Serological (Antibody) Tests for COVID-19 - Letter to Health Care Providers. https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-use-serological-antibody-tests-covid-19-letter-health-care-providers. Accessed April 27, 2020.
69
Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6:CD013652.
70
U.S. Food & Drug Administration. FDA Statement. Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-antigen-test-help-rapid-detection-virus-causes. Accessed May 11, 2020.
71
U.S. Food & Drug Administration. FDA News Release. Coronavirus (COVID-19) Update: FDA Issues First Emergency Authorization for Sample Pooling in Diagnostic Testing. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-first-emergency-authorization-sample-pooling-diagnostic. Accessed July 27, 2020.
72
Nahum J, Morichau-Beauchant T, Daviaud F, et al. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020;3(5):e2010478.
73
Zhang L, Feng X, Zhang D, et al. Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome. Circulation. 2020;142(2):114-128.
74
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed October 14, 2020.
75
U.S. Food & Drug Administration. FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19. Accessed November 16, 2020.
76
Lamontagne F, Agoritsas T, Macdonald H, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.
77
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Sep 2. doi: 10.1001/jama.2020.17023. Epub ahead of print. 
78
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 [published online ahead of print, 2020 May 27]. N Engl J Med. 2020;10.1056/NEJMoa2015301.
79
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial [published online ahead of print, 2020 Aug 21]. JAMA. 2020;10.1001/jama.2020.16349.
80
WHO Solidarity trial consortium, Pan H, Peto R, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020.10.15.20209817; doi: https://doi.org/10.1101/2020.10.15.20209817.
81
U.S. Food & Drug Administration. FDA News Release. FDA Approves First Treatment for COVID-19. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Accessed October 26, 2020.
82
Mustafa AK, Alexander PJ, Joshi DJ, et al. Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure [published online ahead of print, 2020 Aug 11]. JAMA Surg. 2020;10.1001/jamasurg.2020.3950.
83
Mather JF, Seip RL, McKay RG. Impact of Famotidine Use on Clinical Outcomes of Hospitalized COVID-19 Patients. Am J Gastroenterol. 2020 Aug 14. https://journals.lww.com/ajg/Documents/AJG-20-2074_R1.pdf. Accessed August 24, 2020.
84
Yeramaneni S, Doshi P, Sands K, et al. Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized COVID-19 Patients from a Large Healthcare System. Gastroenterology. 2020 Oct 12:S0016-5085(20)35249-5.
85
Chow JH, Khanna AK, Kethireddy S, et al. Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19. Anesth Analg. 2020 Oct 21. doi: 10.1213/ANE.0000000000005292. Epub ahead of print.
86
Monk PD, Marsden RJ, Tear VJ, et al; Inhaled Interferon Beta COVID-19 Study Group. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020 Nov 12:S2213-2600(20)30511-7. doi: 10.1016/S2213-2600(20)30511-7. Epub ahead of print.
87
Cortegiani A, Ippolito M, Ingoglia G, et al. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19 [published online ahead of print, 2020 Jul 11]. J Crit Care. 2020;59:176-190.
88
Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial [published online ahead of print, 2020 Jul 16]. Ann Intern Med. 2020;M20-4207.
89
Solerte SB, D'Addio F, Trevisan R, et al. Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care. 2020 Sep 29:dc201521. doi: 10.2337/dc20-1521. Epub ahead of print.
90
Rajendran K, Krishnasamy N, Rangarajan J, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review [published online ahead of print, 2020 May 1]. J Med Virol. 2020;10.1002/jmv.25961.
91
Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. Preprint. medRxiv. 2020;2020.08.12.20169359. Published 2020 Aug 12.
92
Agarwal A, Mukherjee A, Kumar G, et al; PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020 Oct 22;371:m3939.
93
Ettman CK, Abdalla SM, Cohen GH, et al. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open. 2020;3(9):e2019686.
94
Rajpal S, Tong MS, Borchers J, et al. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection. JAMA Cardiol. Published online September 11, 2020.
95
Centers for Disease Control and Prevention. Coronavirus Disease 2019: Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19. Decision Memo. https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html?deliveryName=USCDC_2067-DM27395. Accessed May 5, 2020.
96
American Academy of Pediatrics. COVID-19 Interim Guidance: Return to Sports. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-interim-guidance-return-to-sports.Accessed September 23, 2020.
97
Heart Failure Society of America. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology. https://hfsa.org/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise. Accessed March 28, 2020.
98
Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382(25):2441-2448.
99
Li J, Wang X, Zhang H, et al. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for Coronavirus Disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5(7):1-6. 
100
Zhang SX, Wang Y, Rach A, et al. Unprecedented disruption of lives and work: Health, distress and life satisfaction of working adults in China one month into the COVID-19 outbreak. Psychiatry Res. 2020;288.
101
Blackburn J, Yiannoutsos CT, Carroll AE, et al. Infection Fatality Ratios for COVID-19 Among Noninstitutionalized Persons 12 and Older: Results of a Random-Sample Prevalence Study [published online ahead of print, 2020 Sep 2]. Ann Intern Med. 2020;10.7326/M20-5352.
102
Bixler D, Miller AD, Mattison CP, et al; Pediatric Mortality Investigation Team. SARS-CoV-2-Associated Deaths Among Persons Aged <21 Years - United States, February 12-July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-1329. 
103
Omer SB, Malanai P, Del Rio C. The COVID-19 pandemic in the US: A clinical update. JAMA. 2020 Apr 6. [Epub ahead of print]
104
Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020 Mar 21. [Epub ahead of print]
105
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19 [published online ahead of print, 2020 Jul 21] [published correction appears in N Engl J Med. 2020 Jul 23;:]. N Engl J Med. 2020;10.1056/NEJMc2025179.
106
Bölke E, Matuschek C, Fischer JC. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med. 2020 Sep 23;383(16):10.1056/NEJMc2027051#sa1.
107
Weinberger DM, Chen J, Cohen T, et al. Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020 [published online ahead of print, 2020 Jul 1]. JAMA Intern Med. 2020;e203391.
108
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 Mar 26;368:m1091.
109
Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study [published online ahead of print, 2020 Jun 25] [published correction appears in Lancet Psychiatry. 2020 Jul 14;:]. Lancet Psychiatry. 2020;S2215-0366(20)30287-X. 
110
Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611-627.
111
Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19 [published online ahead of print, 2020 Jul 9]. JAMA. 2020;e2012603.

ADDITIONAL READING

SEE ALSO

CODES

CLINICAL PEARLS

  • Coronavirus Disease 2019 (COVID-19) is a severe acute respiratory syndrome which originated in China and has spread world-wide, causing a pandemic.

  • The disease results from a novel virus, newly named coronavirus 2 (SARS-CoV-2).

  • The syndrome may lead to death, particularly in elderly and immune-compromised individuals.

  • PCR test sensitivity is low, so consider pre-test probability, especially in evaluating negative results, and recommend self-quarantine for those with a high-risk exposure and/or symptoms.

  • For any patients meeting criteria for evaluation of COVID-19, contact and collaborate with state or local health department.

 
×